| Literature DB >> 23300608 |
Jun Yin1, Lisa Shine, Francis Raycroft, Sudhakar Deeti, Alison Reynolds, Kristin M Ackerman, Antonino Glaviano, Sean O'Farrell, Olivia O'Leary, Claire Kilty, Ciaran Kennedy, Sarah McLoughlin, Megan Rice, Eileen Russell, Desmond G Higgins, David R Hyde, Breandan N Kennedy.
Abstract
Our objective was to profile genetic pathways whose differential expression correlates with maturation of visual function in zebrafish. Bioinformatic analysis of transcriptomic data revealed Jak-Stat signalling as the pathway most enriched in the eye, as visual function develops. Real-time PCR, western blotting, immunohistochemistry and in situ hybridization data confirm that multiple Jak-Stat pathway genes are up-regulated in the zebrafish eye between 3-5 days post-fertilisation, times associated with significant maturation of vision. One of the most up-regulated Jak-Stat genes is the proto-oncogene Pim1 kinase, previously associated with haematological malignancies and cancer. Loss of function experiments using Pim1 morpholinos or Pim1 inhibitors result in significant diminishment of visual behaviour and function. In summary, we have identified that enhanced expression of Jak-Stat pathway genes correlates with maturation of visual function and that the Pim1 oncogene is required for normal visual function.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23300608 PMCID: PMC3530609 DOI: 10.1371/journal.pone.0052177
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Maturation of visual function and correlations to gene expression in larval zebrafish.
(A) The morphology of the zebrafish retina shows no significant changes from 3–5 dpf. However, the OKR (B) and the VMR (C) show significant increases in the number of eye saccades or the amplitude of locomotor responses to light changes from 3–5 dpf. Lights on is shown as a yellow bar below the diagram, and lights off is shown as a black bar. (D–H) Overview of microarray results of eye gene expression for 3, 4 and 5 dpf zebrafish eyes. (D) Hierarchical clustering of gene expression was based on normalized signals (z-scores) using the correlation similarity metric and average linkage clustering. (E) Venn diagram showing the number of up-regulated and down-regulated transcript-level probe sets between pairwise comparisons using the limma Bayesian model based t-test. (F–H) Log2 transformed signal intensities of probe sets are depicted as dots, with up-regulated probe sets in red and down-regulated sets in green.
Top 50 differentially expressed genes between 5 versus 3 dpf.
| Gene Symbol | Description | Log2(Fold Change) | Q-value | Chromosome location | Adhesion | Cell cycle | Death | Development | Muscle development and system process | Regulation | Response to stress/stimulus | Signal transduction | Transcription | Transport | Vision and light stimulus |
|
| crystallin, gamma A | 7.390 | 0.0000 | chr9:23050725-23051699 | |||||||||||
|
| BCL2-related ovarian killer b | 3.670 | 0.0001 | chr2:22097899-22108106 | + | + | |||||||||
|
| dual specificity phosphatase 5 | 3.010 | 0.0002 | chr22:32600889-32612552 | + | + | + | + | |||||||
|
| bHLH-PAS type transcription factor NXF;neuronal PAS domain protein 4 | 2.940 | 0.0001 | chr14:31506584-31512448 | + | + | + | + | |||||||
|
| keratin 17 | 2.340 | 0.0001 | chr22:11866189-11869262 | + | ||||||||||
|
| myosin regulatory light chain interacting protein a | 2.330 | 0.0002 | chr19:26826400-26864319 | + | + | |||||||||
|
| BCL2/adenovirus E1B 19 kDa interacting protein 3 | 2.310 | 0.0002 | chr17:20061572-20066455 | + | ||||||||||
|
| period homolog 2 (Drosophila) | 2.280 | 0.0000 | chr2:48423773-48489628 | + | + | + | + | |||||||
|
| neuropeptide Y | 2.230 | 0.0002 | chr19:20594043-20596307 | + | + | + | + | |||||||
|
| vacuolar protein sorting 37A | 2.160 | 0.0002 | chr1:15204974-15222186 | + | ||||||||||
|
| protein phosphatase 1, regulatory (inhibitor) subunit 3Cb | 1.910 | 0.0001 | chr12:17355562-17359901 | + | ||||||||||
|
| folliculin interacting protein 1 | 1.890 | 0.0001 | chr21:43649629-43693555 | |||||||||||
|
| B-cell translocation gene 2 | 1.870 | 0.0002 | chr22:754597-757144 | + | + | + | ||||||||
|
| transmembrane protein 38B | 1.760 | 0.0001 | chr21:408193-432534 | + | ||||||||||
|
| capicua homolog (Drosophila) | 1.690 | 0.0001 | chr19:6708080-6751038 | |||||||||||
|
| tetraspanin 7 | −1.470 | 0.0002 | chr14:43002970-43012025 | + | + | + | ||||||||
|
| SEC11 homolog A (S. cerevisiae) | −1.490 | 0.0002 | chr18:26732450-26742083 | + | ||||||||||
|
| CD248 molecule,endosialin | −1.680 | 0.0001 | chr7:19379515-19382595 | |||||||||||
|
| solute carrier family 43, member 1a | −1.700 | 0.0002 | chr14:23079820-23101389 | + | + | |||||||||
|
| chondroitin sulfate N-acetylgalactosaminyltransferase 1 | −1.830 | 0.0001 | chr10:7319768-7382081 | |||||||||||
|
| angiopoietin-like 7 | −1.890 | 0.0001 | chr8:48371745-48375260 | + | + | + | ||||||||
|
| tubulin, beta 5 | −1.900 | 0.0001 | chr16:11935792-11944618 | + | + | + | + | |||||||
|
| procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1a | −1.940 | 0.0001 | chr8:50009081-50055886 | + | + | |||||||||
|
| matrix metalloproteinase 2 | −2.000 | 0.0001 | chr7:36864730-36887592 | + | ||||||||||
|
| mesencephalic astrocyte-derived neurotrophic factor | −2.010 | 0.0001 | chr22:35034584-35041263 | + | ||||||||||
|
| SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1 | −2.010 | 0.0001 | chr8:30484009-30502207 | + | ||||||||||
|
| calreticulin like | −2.030 | 0.0002 | chr2:55840094-55855004 | |||||||||||
|
| periostin, osteoblast specific factor | −2.070 | 0.0001 | chr15:33133895-33162913 | + | + | + | ||||||||
|
| collagen, type XI, alpha 1 | −2.400 | 0.0001 | chr24:29686546-29815838 | + | + | + | ||||||||
|
| collagen, type IX, alpha 3 | −2.500 | 0.0001 | chr23:511310-541067 | + | + | |||||||||
|
| procollagen, type IX, alpha 2 | −2.510 | 0.0000 | chr19:39970826-40017220 | + | + | |||||||||
|
| FK506 binding protein 9 | −2.780 | 0.0000 | chr19:44193712-44210392 | |||||||||||
|
| troponin T1, skeletal, slow | −2.790 | 0.0001 | chr4:11096482-11098385 | |||||||||||
|
| leukocyte cell derived chemotaxin 1 | −3.070 | 0.0001 | chr9:55750086-55771208 | + | + | |||||||||
|
| SVOP-like | −3.070 | 0.0001 | chr4:8831282-8843368 | + | ||||||||||
|
| collagen type II, alpha-1a | −3.100 | 0.0001 | chr8:21733311-21757616 | + | + | + | + | + | ||||||
|
| spondin 2b, extracellular matrix protein | −3.240 | 0.0000 | chr14:15209327-15214896 | + | + | + | ||||||||
|
| asporin (LRR class 1) | −3.250 | 0.0000 | chr22:10590115-10597661 | + | + | |||||||||
|
| FK506 binding protein 10 | −3.420 | 0.0001 | chr12:15014462-15064192 | |||||||||||
|
| hyaluronan and proteoglycan link protein 1a | −3.470 | 0.0000 | chr5:48101733-48116816 | + | ||||||||||
|
| anterior gradient homolog 2 (Xenopuslaevis) | −3.590 | 0.0001 | chr19:31646945-31649496 | + | + | |||||||||
|
| antigen p97 (melanoma associated) | −3.970 | 0.0000 | chr6:29805821-29824526 | + | + | |||||||||
|
| troponin T3a, skeletal, fast | −4.150 | 0.0000 | chr25:32248470-32261728 | + | + | |||||||||
|
| goosecoid | −4.230 | 0.0001 | chr17:19173173-19175672 | + | + | + | + | |||||||
|
| tropomyosin 3 | −4.440 | 0.0001 | chr19:11477764-11521373 | + | + | |||||||||
|
| −4.650 | 0.0000 | chr10:44748006-44768991 | + | + | ||||||||||
|
| actin, alpha 1a, skeletal muscle | −4.840 | 0.0000 | chr1:54512581-54520512 | + | + | + | + | |||||||
|
| myosin, light chain 1, alkali; skeletal, fast | −5.130 | 0.0000 | chr9:40046541-40057692 | + | + | |||||||||
|
| heart and neural crest derivatives expressed transcript 2 | −5.410 | 0.0000 | chr1:38602300-38604523 | + | + | + | + | |||||||
|
| matrilin 1 | −8.310 | 0.0001 | chr19:45245318-45268889 |
: these differentially expressed genes were verified using real-time PCR in our previous study [11].
Top 20 unknown differentially expressed genes between 5 versus 3 dpf and their human homologs identified using BLASTX.
| Gene Symbol | Representative Accession ID | Chromosome Location | Log2 (Fold Change) | Q-value | Human homolog identified using BLASTX | |||
| RefSeq ID | Protein Symbol | Description | BLASX Evalue | |||||
| LOC557783 | ENSDART00000022660 | chr3:32595697-32608941 | 3.300 | 0.0004 | NP_068751 | RIC8A | resistance to inhibitors of cholinesterase 8 homolog A (C. elegans) | 4.00E-110 |
| si:ch211-237l4.6 | NM_001033091 | chr10:22982732-22986656 | 3.150 | 0.0001 | ||||
| c8orf4 | ENSDART00000111097 | chr10:20290365-20291110 | 3.050 | 0.0002 | NP_064515 | C8orf4 | chromosome 8 open reading frame 4 | 1.00E-15 |
| LOC 556873 | BC083258 | chr17:30528306-30532467 | 2.800 | 0.0006 | NP_955378 | PFN4 | profilin family, member 4 | 2.00E-24 |
| fam169a | ENSDART00000124807 | chr21:14073809-14104257 | 2.670 | 0.0005 | NP_056381 | FAM169A | family with sequence similarity 169, member A | 4.00E-90 |
| zgc:113162 | NM_001020714 | chr21:11590062-11634648 | 2.600 | 0.0004 | NP_009101 | TESK2 | testis-specific kinase 2 | 3.00E-70 |
| LOC 556200 | ENSDART00000123381 | chr11:39739623-39745008 | 2.370 | 0.0003 | ||||
| b8ji39_danre | ENSDART00000049885 | chr7:24744813-24893012 | 2.020 | 0.0004 | NP_690618 | DGKD | diacylglycerol kinase, delta 130 kDa | 0.00E+00 |
| zgc:165666 | NM_001099242 | chr3:46422259-46441887 | 1.690 | 0.0004 | NP_037531 | C16orf5 | chromosome 16 open reading frame 5 | 9.00E-75 |
| zgc:73324 | NM_200789 | chr3:17752915-17759753 | 1.670 | 0.0002 | NP_079423 | COQ10B | coenzyme Q10 homolog B (S. cerevisiae) | 2.00E-57 |
| zgc:162945 | NM_001128809 | chr7:31606262-31609395 | 1.660 | 0.0009 | NP_776172 | HARBI1 | harbinger transposase derived 1 | 7.00E-46 |
| si:ch211-195b13.1 | NM_001077302 | chr19:25368491-25374891 | 1.630 | 0.0007 | NP_005618 | SGK1 | serum/glucocorticoid regulated kinase 1 | 2.00E-173 |
| si:dkey-177p2.6 | NM_001075116 | chr20:26977416-26992361 | 1.580 | 0.0010 | NP_055570 | SERTAD2 | SERTA domain containing 2 | 3.00E-20 |
| zgc:110006 | NM_001020552 | chr10:36077772-36132111 | 1.520 | 0.0008 | NP_001093890 | C21orf91 | chromosome 21 open reading frame 91 | 7.00E-72 |
| LOC 569602 | ENSDART00000011398 | chr7:21304641-21382962 | 1.290 | 0.0012 | NP_005535 | IRS1 | insulin receptor substrate 1 | 6.00E-155 |
| zgc:112372 | NM_001020768 | chr3:61284536-61316553 | 1.260 | 0.0013 | NP_872371 | FAM100B | family with sequence similarity 100, member B | 8.00E-56 |
| si:ch211-11k18.4 | ENSDART00000121613 | chr3:26851370-26860356 | −1.760 | 0.0002 | NP_001092284 | SRL | sarcalumenin | 2.00E-05 |
| wu:fb15e04 | ENSDART00000124926 | chr21:24464941-24474823 | −2.510 | 0.0003 | NP_476429 | KRT3 | keratin 3 | 5.00E-77 |
| zgc:112964 | NM_001013342 | chr16:2281217-2297724 | −3.510 | 0.0000 | NP_001073906 | SNED1 | sushi,nidogen and EGF-like domains 1 | 3.00E-28 |
| si:ch211-243g18.2 | NM_001044910 | chr10:9640875-9661489 | −3.640 | 0.0000 | NP_000413 | KRT17 | keratin 17 | 2.00E-72 |
Zebrafish genes differentially expressed between 5 and 3 dpf were associated with human retinal diseases without molecular basis.
| Diseases | OMIM ID | Chromosmal location | Homologous zebrafish genes differentially expressed between 5 and 3 dpf |
| Retinitis pigmentosa with mental retardation | Xp21-q21 |
| |
| Dominant macular dystrophy, North Carolina type; dominant progressive bifocal chorioretinal atrophy | 136550 | 6q14-q16.2 |
|
| Dominant macular dystrophy, cystoid | 153880 | 7p21-p15 |
|
| Dominant retinal-cone dystrophy 1 | 180020 | 6q25-q26 |
|
| Dominant neovascular inflammatory vitreoretinopathy | 193235 | 11q13 |
|
| Recessive Joubert syndrome; recessive MORM syndrome | 213300 | 9q34.3 |
|
| Recessive nonsyndromal congenital retinal nonattachment | 221900 | 10q21 |
|
| Recessive optic atrophy | 258500 | 8q21-q22 |
|
| X-linked progressive cone dystrophy 2 | 300085 | Xq27 |
|
| X-linked retinitis pigmentosa | 300155 | Xq26-q27 |
|
| X-linked retinitis pigmentosa | 300424 | Xp22 |
|
| X-linked retinitis pigmentosa | 300605 | Xq28-qter |
|
| X-linked optic atrophy | 311050 | Xp11.4-p11.2 |
|
| Cone-rod dystrophy; de grouchy syndrome | 600624 | 18q21.1-q21.3 |
|
| Dominant macular dystrophy, North Carolina type; dominant progressive bifocal chorioretinal atrophy | 600790 | 6q14-q16.2 |
|
| Recessive Refsum disease, adult form | 600964 | 10p13 |
|
| Recessive Usher syndrome, type 1 | 602097 | 21q21 |
|
| Recessive retinitis pigmentosa | 602594 | 16p12.3-p12.1 |
|
| Recessive retardation, spasticity and retinal degeneration | 602685 | 15q24 |
|
| Dominant optic atrophy,Kjer type | 605293 | 18q12.2-q12.3 |
|
| Recessive cone-rod dystrophy | 605549 | 1q23.1-q23.3 |
|
| Dominant familial exudative vitreoretinopathy | 605750 | 11p13-p12 |
|
| Recessive retinitis pigmentosa | 606068 | 2p15 |
|
| Recessive Senior-Loken syndrome; recessive nephronophthisis, Adolescent | 606995 | 3q22.1 |
|
| Recessive Joubert syndrome | 608091 | 11p12-q13.3 |
|
| Recessive Leber congenital amaurosis | 608553 | 1p36 |
|
| Dominant macular dystrophy, late onset; dominant macular dystrophy with lens zonules; | 608752 | 11q23.3 |
|
| Dominant macular dystrophy | 608850 | 5p15.33-p13.1 |
|
| Recessive retinitis pigmentosa with posterior column ataxia (PCARP) | 609033 | 1q32.3 |
|
| Recessive foveal hypoplasia and anterior segment dysgenesis | 609218 | 16q23.2-q24.2 |
|
| Recessive retinitis pigmentosa, severe | 609913 | 1p21.2-p13.3 |
|
| Dominant retinitis pigmentosa | 610359 | 2q11.2 |
|
| Dominant optic atrophy | 610708 | 22q12.1-q13.1 |
|
| Dominant cavitary optic disc anomalies | 611543 | 12q13.13-q14.3 |
|
| Dominant macular dystrophy, benign concentric annular | 6p12.3-q16 |
| |
| Cone-rod dystrophy | 17q |
| |
| Dominant macular dystrophy, North Carolina-like with progressive sensorineural hearing loss | 14q11.2 |
| |
| Dominant macular dystrophy | 19q13.31-q13.32 |
| |
| Recessive retinitis pigmentosa | 4q32-q34 |
| |
| Recessive vitreoretinal dystrophy | 22q13 |
| |
| Recessive retinitis pigmentosa | 2p23.3 |
|
Figure 2Summary of differentially expressed genes between 5 versus 3 dpf eyes using GO biological process annotation.
A, B: GO summary for up-regulated genes between 5 versus 3 dpf. C, D: GO summary for down-regulated genes between 5 versus 3 dpf. A, C: pie chart presenting the number of differentially expressed genes in each GO category. B, D: bar plot presenting the significance of each GO term in Q-values. Q-value<0.05 was set as the significance threshold as depicted by the red dashed line.
Top 3 over represented GO terms by the differentially expressed genes between 5 versus 3 dpf for each GO category.
| GO term | No. of differentially expressed genes in the GO term | No. of all genes annotated with the GO term | Q-value |
|
| |||
|
| |||
| GO:0050896 response to stimulus | 22 | 62 | 0.0014 |
| GO:0060337 type I interferon-mediated signaling pathway | 9 | 13 | 0.0014 |
| GO:0034097 response to cytokine stimulus | 11 | 19 | 0.0014 |
| GO:0009416 response to light stimulus | 12 | 23 | 0.0016 |
|
| |||
| GO:0005576 extracellular region | 54 | 285 | 0.0547 |
| GO:0005741 mitochondrial outer membrane | 13 | 43 | 0.0680 |
| GO:0005740 mitochondrial envelope | 6 | 12 | 0.0680 |
| GO:0030133 transport vesicle | 5 | 10 | 0.0993 |
|
| |||
| GO:0003913 DNA photolyase activity | 7 | 9 | 0.0028 |
| GO:0046983 protein dimerization activity | 14 | 41 | 0.0279 |
| GO:0008236 serine-type peptidase activity | 8 | 18 | 0.0536 |
| GO:0004114 3,5-cyclic-nucleotide phosphodiesterase activity | 4 | 5 | 0.0547 |
|
| |||
|
| |||
| GO:0000278 mitotic cell cycle | 61 | 159 | 0.0000 |
| GO:0000082 G1/S transition of mitotic cell cycle | 44 | 94 | 0.0000 |
| GO:0031145 anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process | 35 | 65 | 0.0000 |
| GO:0000216 M/G1 transition of mitotic cell cycle | 33 | 62 | 0.0000 |
|
| |||
| GO:0000502 proteasome complex | 28 | 48 | 0.0000 |
| GO:0005783 endoplasmic reticulum | 91 | 343 | 0.0000 |
| GO:0005788 endoplasmic reticulum lumen | 22 | 43 | 0.0000 |
| GO:0005581 collagen | 10 | 11 | 0.0000 |
|
| |||
| GO:0008307 structural constituent of muscle | 12 | 18 | 0.0000 |
| GO:0005201 extracellular matrix structural constituent | 11 | 16 | 0.0000 |
| GO:0005509 calcium ion binding | 50 | 191 | 0.0000 |
| GO:0000166 nucleotide binding | 145 | 783 | 0.0002 |
Significantly over represented KEGG pathway by the differentially expressed genes between 5 versus 3 dpf.
| KEGG Pathway | No. of differentially expressed genes in the pathway | No. of all genes annotated with the pathway | Q-value |
|
| |||
| Jak-Stat signaling pathway | 13 | 29 | 0.0012 |
| Insulin signaling pathway | 21 | 70 | 0.0021 |
| Pancreatic secretion | 14 | 39 | 0.0036 |
| MAPK signaling pathway | 25 | 98 | 0.0038 |
| Arginine and proline metabolism | 12 | 32 | 0.0044 |
|
| |||
| Proteasome | 26 | 39 | 0.0000 |
| Dilated cardiomyopathy | 13 | 22 | 0.0003 |
| ECM-receptor interaction | 12 | 21 | 0.0007 |
| Hypertrophic cardiomyopathy (HCM) | 13 | 25 | 0.0009 |
| Protein processing in endoplasmic reticulum | 34 | 112 | 0.0012 |
Figure 3Up-regulation of gene and protein expression in the Jak-Stat signaling pathway from 3 to 5 dpf during eye development.
(A) Red blocks are up-regulated genes between 5 versus 3 dpf. Green blocks are down-regulated genes between 5 versus 3 dpf. Grey blocks are genes not changed between 5 versus 3 dpf. White blocks are genes not targeted by the microarray or not in the zebrafish genome. The gene interaction network figure is from the KEGG database with modification adapted to zebrafish genes. (B) Signal intensities on the microarrays. *: q-value<0.05. **: q-value<0.01. (C) Real-time PCR results are depicted as relative abundance compared to lowest abundance sample. *: p-value<0.05. **: p-value<0.01. (D) Western blot and (E) densitometric analysis of protein samples extracted from zebrafish whole larvae shows that Socs1, Socs3a and Stat3 expression are up-regulated from 2 to 7 dpf.
Figure 4Socs3a, Socs1 and Stat3 expression in 2–7 dpf retina.
First five panels are immunohistochemical analysis showing increasing expression of Socs3a, Socs1 and Stat3 throughout the retina from 2–7 dpf. Minimal staining is observed in secondary antibody alone, pre-immune serum or morphant controls. The last three panels are in-situ hybridisations of socs3a, socs1 and stat3 genes on 2 and 7 dpf. No significant staining was observed in sense probe controls. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
Figure 5Cell types in Socs1, Socs3a and Stat3 morphant retinae. Socs1, Socs3a and Stat3 morphant retinae were labelled with rhodopsin for photoreceptors, gfap:GFP for Muller glia, Hu for inner retinal neurons and TUNEL staining for apoptotic cells.
Scale bar in the upper left panel represents 50 microns and is the same for all the panels.
Figure 6Sequence and structure analysis of Pim protein family.
(A) Neighbor-joining tree with 1000 bootstrap resamplings. Subgroups for Pim1, Pim2 and Pim3 proteins are highlighted in different colors. C. elegans Prk proteins were used to root the tree. (B) The 3-D structure of zebrafish Pim1 protein was predicted by homology modeling using Swiss-Model [29] using the human PIM1 crystal structure 3BGP as the template. Estimated accuracy in Qmean value was colored from blue to red. A lower Qmean value indicates more reliable prediction. The Pim1 inhibitor 2 drug docking site was predicted using SwissDock [32]. (C) Chemical structure of Pim1 inhibitor 2. (D) Chemical structure of Pim1 inhibitor II. (E) Sequence alignment of zebrafish Pim proteins with human PIM1 with assigned secondary structure. Residues within 4.5 Å of the Pim1 inhibitor 2 docking site are highlighted in grey in human and zebrafish Pim1.The Pim1 antibody-binding site is highlighted using a rectangle.
Figure 7Localisation of Pim1 in the larval eye.
(A) Immunohistochemical analysis of Pim1 protein (red) and DAPI (blue) in 3 and 5 dpf larval eyes reveals Pim1 expression throughout the neuoretina including the ganglion cell layer (arrow) and inner nuclear layer (arrowhead) at both timepoints. (B) Pim1 RNA is expressed in the INL, GCL and CMZ of 2 and 5 dpf larvae. (C) RT-PCR amplification of pim1 from 5 dpf cDNA results in a 1059 bp band in control morpholino-injected larvae and a second ∼500 bp band in pim1 splice site morpholino-injected larvae consistent with knockdown of pim1.(D) Pim1 expression is present in the ONL, INL and GCL of 5 dpf larvae injected with 0.025 mM standard control morpholino but highly reduced in 5 dpf larvae injected with 0.025 mM pim1 morpholino. White boxes indicate the areas magnified. MO, morpholino; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer; CMZ, ciliary marginal zone; L, lens.
Figure 8Larvae treated with Pim1 inhibitors have a slightly reduced number of primary hyaloid vessels and eye size.
(A) Representative images of whole zebrafish larvae treated using Pim1 inhibitors. (B) and (C) zebrafish (n = 17 to 20) treated with Pim1 inhibitor 2 from 3–5 dpf have normal hyaloid vasculature morphology, while treatment with Pim1 inhibitor II from 3–5 dpf slightly reduces the number of primary hyaloid vessels. Primary hyaloid vessels are pointed using asterisks. P-value was calculated using one way ANOVA with Dunnett's correction for multiple comparisons. *:ANOVA p<0.05. (D) Zebrafish larvae treated with Pim1 Inhibitor 2 from 3–5 dpf have a smaller eye. ***: Student's t test p<0.001. (E) Retinal lamination appears normal in the larvae with drug-treated from 3–5 dpf. Scale bars are 1 mm (A) and 50 mm (E).
Figure 9Pim1 inhibition results in a reduced visual response at 5 dpf.
(A) The OKR of Pim1 MO injected fish is significantly reduced. Larvae were treated with increasing concentrations of Pim1 inhibitor 2 or Pim1 inhibitor II ranging from 1 to 100 µM. Pim1 inhibitors were dissolved in 0.1% DMSO at all concentrations except the 100 µM concentration which was dissolved in 1% DMSO. (B) The ERG a-wave and b-wave are significantly decreased in 100 µM Pim1 inhibitor 2 treated fish. (C–J), significant reduction of OKR saccades in zebrafish treated from 3–5 dpf (“chronic”) or treated for 1 hour at 5 dpf (“acute”) using Pim1 inhibitors. The locomotor touch response of fish treated with Pim1 inhibitors is unaltered. p-values were calculated using Student's t test. *: p<0.05. **: p<0.01. ***: p<0.001.
Figure 10Pim1 inhibition results in reversible reduction of VMR on and off peaks.
Zebrafish (n = 36 to 60) were treated from 3–5 dpf (“chronic”) or at 5 dpf for 1 hour (“acute”) using Pim1 inhibitors. (A–L) The ON and OFF response are significantly reduced in zebrafish treated using Pim1 inhibitors compared to zebrafish treated with DMSO control. p-values were calculated using Wilcoxon rank sum test with Bonferroni correction for multiple testing. *: p<0.05, **: p<0.01. (M) After 1 hour Pim1 inhibitor II treatment at 5 dpf, zebrafish larvae were washed with embryo medium and settled for 7–8 hours before the VMR was re-tested. After removal of Pim1 inhibitor II, zebrafish showed significantly recovered ON and OFF responses. p-values were calculated using Wilcoxon rank sum test. *: p<0.1. **: p<0.01.